Eli Lilly reported full results from its phase 2 SYNERGY-MASH trial of GLP-1 and GIP agonist tirzepatide – already on the market as Mounjaro for diabetes and Zepbound for obesity – in biopsy ...

Following a similar decision in case the trade group Outsourcing Facilities Association brought against FDA over its decision ...

Where will Eli Lilly be in five years? Despite Lilly's huge success in treating diabetes and obesity, it's not the leader in those markets. That honor belongs to Novo Nordisk ( NVO 1.36%), which sells ...

Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and obese ...

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the ...

Eli Lilly and Co. (LLY) announced that Zepbound (tirzepatide) demonstrated a significantly greater weight reduction compared to Wegovy (semaglutide) in all comparisons conducted during the Phase ...

Continue » Lilly's Mounjaro and Zepbound, which share the same generic drug (tirzepatide ... phase 2 clinical studies as a potential treatment for metabolic-associated steatohepatitis (MASH ...